The effect of pentoxifylline in the treatment of Covid-19 disease

Phase 2

Recruiting

• Conditions: The effect of pentoxifylline in the treatment of covid-19 disease.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20110425006280N11
• Lead Sponsor: Vice President of Research Guilan university of medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients with a clinical diagnosis of respiratory distress and dyspnea with SPAO2 less than 93% or positive PCR and radiographic test on CT SCANNING or Chest X-Ray admitted to the intensive care unit

Exclusion Criteria

pregnant patients
patients who get under therapy for less than 3 days

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical signs of COVID-19 disease. Timepoint: Daily in the morning visit for 14 days. Method of measurement: Observe, measure and record fever, cough, shortness of breath, olfactory and taste disorders, headache, gastrointestinal symptoms, chills and .;Percentage of oxygen saturation. Timepoint: Daily in the morning visit for 14 days. Method of measurement: Based on measurements with pulse oximetery.

Secondary Outcome Measures

Name	Time	Method
Patient`s recovery. Timepoint: Daily in the morning visit for 14 days. Method of measurement: No need for supplemental oxygen or mechanical ventilation and ICU discharge.